Exhibit Explores Healing Power of Creating Artwork
LOS ANGELES--An exhibit featuring works by five women artists who have lived with cancer was displayed in conjunction with the 1998 Oncology Nursing Society and ASCO meetings.
LOS ANGELES--An exhibit featuring works by five women artists who have lived with cancer was displayed in conjunction with the 1998 Oncology Nursing Society and ASCO meetings.
Novartis Oncology sponsored the exhibit, entitled Medicine Cures the Body, Art Heals the Spirit, along with The Creative Center for Women With Cancer, a New York-based nonprofit organization founded on a belief in the healing power of creative activity. The exhibit is part of Novartis Living With Cancer initiative, which provides support to cancer patients, their families, and friends.
The artists include Lise Poirier (Figure1); photographer Susan B. Markisz; Robin Glazer, art director for The Creative Center; Susan Shatter, whose work is on display at the Art Institute of Chicago and other museums; and sculptor Leonda Finke (Figure 2).
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.
